CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease

Júlia Faura, Alejandro Bustamante, Anna Penalba, Dolors Giralt, Alba Simats, Elena Martínez-Sáez, Daniel Alcolea, Juan Fortea, Alberto Lleó, Charlotte E. Teunissen, Wiesje M. Van Der Flier, Laura Ibañez, Oscar Harari, Carlos Cruchaga, Mar Hernández-Guillamón, Pilar Delgado, Joan Montaner

Research output: Contribution to journalArticle

Abstract

CCL23 is a chemokine implicated in inflammation and host defense responses. It has been recently associated with acquired brain damage and stroke outcomes. In this study, we reported the role of CCL23 in Alzheimer's disease (AD). We evaluated the levels of CCL23 in 659 individuals: cognitively normal, mild cognitive impaired (MCI), and AD patients. Two cross-sectional (study 1, n = 53; study 2, n = 200) and two longitudinal (study 3, n = 74; study 4, n = 332) studies were analyzed separately. CCL23 levels in the blood and/or cerebrospinal fluid (CSF) of each study were measured by immunoassays. Globally, our results suggest a predictive role of CCL23 protein levels both in the plasma in study 3 (hazard ratio (HR) = 2.5 (confidence interval (CI) 95% : 1.2-5.3), p = 0.02) and in the CSF in study 4 (HR = 3.05 (CI 95% : 1.02-5), p = 0.04) in cases of MCI that progress to AD. Moreover, we observed that the APOE ϵ4 allele was associated with higher levels of CCL23 in study 2 (470.33 pg/mL (interquartile range (IQR): 303.33-597.76) versus 377.94 pg/mL (IQR: 267.16-529.19), p = 0.01) (APOE genotypes were available in studies 2 and 4). Together, these findings support the role of CCL23 in neuroinflammation in the early stages of AD, suggesting that CCL23 might be a candidate blood biomarker for MCI to AD progression.

Original languageEnglish
Pages (from-to)1585-1595
Number of pages11
JournalJournal of Alzheimer's Disease
Volume73
Issue number4
DOIs
StatePublished - Jan 1 2020

Keywords

  • Alzheimer's disease
  • biomarkers
  • chemokines
  • cognitive dysfunction
  • early diagnosis

Fingerprint Dive into the research topics of 'CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease'. Together they form a unique fingerprint.

  • Cite this

    Faura, J., Bustamante, A., Penalba, A., Giralt, D., Simats, A., Martínez-Sáez, E., Alcolea, D., Fortea, J., Lleó, A., Teunissen, C. E., Van Der Flier, W. M., Ibañez, L., Harari, O., Cruchaga, C., Hernández-Guillamón, M., Delgado, P., & Montaner, J. (2020). CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 73(4), 1585-1595. https://doi.org/10.3233/JAD-190753